| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 935 | 2016 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 589 | 2015 |
| CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors SR Vora, D Juric, N Kim, M Mino-Kenudson, T Huynh, C Costa, ... Cancer cell 26 (1), 136-149, 2014 | 450 | 2014 |
| MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors AB Turke, Y Song, C Costa, R Cook, CL Arteaga, JM Asara, JA Engelman Cancer research 72 (13), 3228-3237, 2012 | 402 | 2012 |
| Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development E Ciraolo, M Iezzi, R Marone, S Marengo, C Curcio, C Costa, O Azzolino, ... Science signaling 1 (36), ra3-ra3, 2008 | 297 | 2008 |
| PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 H Ebi, C Costa, AC Faber, M Nishtala, H Kotani, D Juric, P Della Pelle, ... Proceedings of the National Academy of Sciences 110 (52), 21124-21129, 2013 | 237 | 2013 |
| PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function I Franco, F Gulluni, CC Campa, C Costa, JP Margaria, E Ciraolo, ... Developmental cell 28 (6), 647-658, 2014 | 208 | 2014 |
| Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer C Costa, H Ebi, M Martini, SA Beausoleil, AC Faber, CT Jakubik, A Huang, ... Cancer cell 27 (1), 97-108, 2015 | 207 | 2015 |
| PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer C Costa, Y Wang, A Ly, Y Hosono, E Murchie, CS Walmsley, T Huynh, ... Cancer discovery 10 (1), 72-85, 2020 | 198 | 2020 |
| Phosphoinositide 3-kinases as a common platform for multi-hormone signaling E Hirsch, C Costa, E Ciraolo Journal of Endocrinology 194 (2), 243-256, 2007 | 197 | 2007 |
| mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 AC Faber, EM Coffee, C Costa, A Dastur, H Ebi, AN Hata, AT Yeo, ... Cancer discovery 4 (1), 42-52, 2014 | 142 | 2014 |
| Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer AC Faber, AF Farago, C Costa, A Dastur, M Gomez-Caraballo, R Robbins, ... Proceedings of the National Academy of Sciences 112 (11), E1288-E1296, 2015 | 136 | 2015 |
| EGF816 exerts anticancer effects in non–small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor Y Jia, J Juarez, J Li, M Manuia, MJ Niederst, C Tompkins, N Timple, ... Cancer research 76 (6), 1591-1602, 2016 | 129 | 2016 |
| Exploitation of the apoptosis-primed state of MYCN-amplified neuroblastoma to develop a potent and specific targeted therapy combination J Ham, C Costa, R Sano, TL Lochmann, EM Sennott, NU Patel, A Dastur, ... Cancer cell 29 (2), 159-172, 2016 | 126 | 2016 |
| Venetoclax is effective in small-cell lung cancers with high BCL-2 expression TL Lochmann, KV Floros, M Naseri, KM Powell, W Cook, RJ March, ... Clinical cancer research 24 (2), 360-369, 2018 | 118 | 2018 |
| The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation DP Kodack, V Askoxylakis, GB Ferraro, Q Sheng, M Badeaux, S Goel, ... Science translational medicine 9 (391), eaal4682, 2017 | 106 | 2017 |
| p130Cas mediates the transforming properties of the anaplastic lymphoma kinase C Ambrogio, C Voena, AD Manazza, R Piva, L Riera, L Barberis, C Costa, ... Blood 106 (12), 3907-3916, 2005 | 101 | 2005 |
| Taming the PI3K team to hold inflammation and cancer at bay E Hirsch, E Ciraolo, A Ghigo, C Costa Pharmacology & therapeutics 118 (2), 192-205, 2008 | 100 | 2008 |
| Apoptosis in targeted therapy responses: the role of BIM AC Faber, H Ebi, C Costa, JA Engelman Advances in pharmacology 65, 519-542, 2012 | 80 | 2012 |
| Leukocyte transmigration is modulated by chemokine‐mediated PI3Kγ‐dependent phosphorylation of vimentin L Barberis, C Pasquali, D Bertschy‐Meier, A Cuccurullo, C Costa, ... European journal of immunology 39 (4), 1136-1146, 2009 | 77 | 2009 |
